Insulet (NASDAQ:PODD) Given New $366.00 Price Target at Raymond James Financial

Insulet (NASDAQ:PODD) had its price objective hoisted by analysts at Raymond James Financial from $360.00 to $366.00 in a research note issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Raymond James Financial’s price target would indicate a potential upside of 12.50% from the stock’s current price.

A number of other research analysts have also issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Leerink Partners upped their target price on shares of Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 14th. Truist Financial lifted their price target on Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a report on Friday. Piper Sandler raised their target price on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, Stifel Nicolaus assumed coverage on Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $367.74.

Insulet Stock Performance

PODD stock traded up $1.93 during trading on Friday, hitting $325.33. 68,467 shares of the company’s stock traded hands, compared to its average volume of 718,270. The stock has a market capitalization of $22.90 billion, a price-to-earnings ratio of 99.11, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet has a 52 week low of $230.05 and a 52 week high of $353.50. The stock has a fifty day moving average price of $325.46 and a two-hundred day moving average price of $308.84. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same period in the previous year, the business posted $1.08 EPS. The company’s quarterly revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts anticipate that Insulet will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Insulet

Several institutional investors have recently made changes to their positions in PODD. Vanguard Group Inc. increased its stake in Insulet by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier’s stock valued at $2,735,991,000 after buying an additional 39,403 shares during the period. Geode Capital Management LLC grew its holdings in shares of Insulet by 3.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after acquiring an additional 58,309 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares in the last quarter. Groupama Asset Managment increased its stake in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after acquiring an additional 3,759 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Insulet during the second quarter worth $324,689,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.